Daniel Camardo, Athersys CEO (Horizon)
June 3, 2022 07:24 AM EDT
People

Days af­ter dis­clos­ing tri­al flop, stem cell ther­a­py de­vel­op­er ax­es 70% of work­force while search­ing for cash

Amber Tong

When Daniel Ca­mar­do host­ed his first quar­ter­ly in­vestor call as CEO of Ather­sys, the pic­ture he paint­ed was all rosy: He’s join­ing to “com­plete the …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

WuXi AppTec will sell cell and gene ther­a­py busi­ness to pri­vate eq­ui­ty firm

J&J part­ners on STAT6; As­traZeneca, Dai­ichi with­draw lung can­cer drug EMA app

BioN­Tech set­tles with NIH, UPenn in Covid vac­cine dis­putes and will pay roy­al­ties

FDA ap­proves sub­cu­ta­neous ver­sion of Bris­tol My­er­s' Op­di­vo

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

A service from the Financial Times